{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-021869","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.512194+00:00","generated_at":"2026-05-15T22:30:08.720280+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"United Therapeutics' ralinepag phase 3 meets primary endpoint; 55% risk reduction in PAH clinical worsening","bullets":["Ralinepag reduced risk of clinical worsening by 55% vs placebo (HR 0.45, p<0.0001) in phase 3 ADVANCE OUTCOMES study.","Statistically significant improvements in 6MWD, NT-proBNP, and 47% increased odds of clinical improvement at Week 28.","80% of patients on dual background therapy; safety consistent with prostacyclin class; no new signals.","Company plans to submit NDA to FDA by second half of 2026.","Full results to be presented at upcoming international conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-021869","json":"https://secwatch.observer/filing/0001104659-26-021869.json","markdown":"https://secwatch.observer/filing/0001104659-26-021869.md","text":"https://secwatch.observer/filing/0001104659-26-021869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000110465926021869/0001104659-26-021869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000110465926021869/tm267696d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:30:08.720280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}